133626-87-6 Usage
Chemical class
Benzodiazepine derivative
Structure
Contains an acetyl group and a prop-2-en-1-yl group
Pharmacological properties
Sedative and anxiety-reducing effects
Potential uses
Treatment of anxiety, insomnia, and other related conditions
Risks
Dependence and abuse potential
Medical supervision
Necessary when using for therapeutic purposes
Central nervous system effects
Acts as a central nervous system depressant
Molecular weight
Approximately 291.32 g/mol
Appearance
Likely a solid, possibly crystalline or amorphous
Solubility
Soluble in organic solvents such as methanol, ethanol, or dimethyl sulfoxide (DMSO)
Stability
May be sensitive to light, heat, and moisture
Synthesis
Typically synthesized through chemical reactions involving the core benzodiazepine structure and the addition of the acetyl and prop-2-en-1-yl groups
Metabolism
May be metabolized in the liver by the cytochrome P450 enzyme system, leading to the formation of metabolites that can be excreted in the urine or bile.
Check Digit Verification of cas no
The CAS Registry Mumber 133626-87-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,6,2 and 6 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 133626-87:
(8*1)+(7*3)+(6*3)+(5*6)+(4*2)+(3*6)+(2*8)+(1*7)=126
126 % 10 = 6
So 133626-87-6 is a valid CAS Registry Number.
133626-87-6Relevant articles and documents
Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones
Hargrave, Karl D.,Proudfoot, John R.,Grozinger, Karl G.,Cullen, Ernest,Kapadia, Suresh R.,et al.
, p. 2231 - 2241 (2007/10/02)
Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.
